These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 15734947

  • 1. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
    Gerard SK, Dam HQ.
    Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
    [No Abstract] [Full Text] [Related]

  • 2. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ, Kim SM, Lin HC, Intenzo CM.
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [Abstract] [Full Text] [Related]

  • 3. [Follow-up of children and young adults with differentiated thyroid cancer treated with radioiodine].
    Coronado Poggio M, Martin Curto LM, Marín Ferrer MD, Coya Viña J, Couto Caro RM, Navarro Martínez T, Riesco Almarza G.
    Rev Esp Med Nucl; 2003 Aug; 22(5):316-26. PubMed ID: 14534007
    [Abstract] [Full Text] [Related]

  • 4. Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.
    Zilioli V, Peli A, Panarotto MB, Magri G, Alkraisheh A, Wiefels C, Rodella C, Giubbini R.
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [Abstract] [Full Text] [Related]

  • 5. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
    Muratet JP, Daver A, Minier JF, Larra F.
    J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
    [Abstract] [Full Text] [Related]

  • 6. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [Abstract] [Full Text] [Related]

  • 7. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer.
    Maxon HR.
    Q J Nucl Med; 1999 Dec; 43(4):313-23. PubMed ID: 10731782
    [Abstract] [Full Text] [Related]

  • 8. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
    Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F.
    J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
    [Abstract] [Full Text] [Related]

  • 9. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M, Ricard M, Leboulleux S, Baudin E, Schlumberger M.
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [Abstract] [Full Text] [Related]

  • 10. [Differentiated thyroid cancers].
    Gorgone S, Campennì A, Calbo E, Catalfamo A, Sciglitano P, Sofia L, Niceta M, Borzì R, Calbo L.
    G Chir; 2009 Aug; 30(1-2):26-9. PubMed ID: 19272228
    [Abstract] [Full Text] [Related]

  • 11. Surveillance of patients to detect recurrent thyroid carcinoma.
    Grigsby PW, Baglan K, Siegel BA.
    Cancer; 1999 Feb 15; 85(4):945-51. PubMed ID: 10091774
    [Abstract] [Full Text] [Related]

  • 12. Assessment of the efficacy of iodine-131 for thyroid ablation.
    Comtois R, Thériault C, Del Vecchio P.
    J Nucl Med; 1993 Nov 15; 34(11):1927-30. PubMed ID: 8229236
    [Abstract] [Full Text] [Related]

  • 13. Accumulation of (131)INa activity in renal cysts unrelated to metastatic disease in a patient with differentiated thyroid cancer.
    Castillo-Berrio C, Zelaya F, Loira F, Castrillón M, López A, Outomuro J.
    Rev Esp Med Nucl Imagen Mol; 2016 Nov 15; 35(1):70-1. PubMed ID: 26144698
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
    Silberstein EB.
    J Nucl Med; 2007 Jul 15; 48(7):1043-6. PubMed ID: 17574976
    [Abstract] [Full Text] [Related]

  • 15. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK, Murby B.
    J Clin Endocrinol Metab; 2014 Jul 15; 99(7):2433-40. PubMed ID: 24762114
    [Abstract] [Full Text] [Related]

  • 16. [Recurrences and metastases in differentiated thyroid cancer].
    Petkov R.
    Khirurgiia (Sofiia); 1995 Jul 15; 48(2):8-10. PubMed ID: 8531449
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R.
    Rev Esp Med Nucl; 2007 Jul 15; 26(3):138-45. PubMed ID: 17524307
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV, Osborne R, Ahn E, Avitia S, Juillard G.
    Ear Nose Throat J; 2009 Jul 15; 88(7):E01. PubMed ID: 19623515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.